Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MS Contin · 1 trial · 1 indication
Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 millimeter (mm) bipolar visual analogue scale (VAS) anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hours (hrs) (0-2).
Drug liking assesses the degree that a participant likes a drug effect at the time the question is being asked (that is, at the moment). It is scored using a 100 mm bipolar VAS anchored in the center with a neutral anchor of "neither like nor dislike" (score of 50 mm), on the left with "strong disliking" (score of 0 mm) and on the right with "strong liking" (score of 100 mm). Emax = Maximum observed score.
High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). AUE (0-2) = Area under the effect versus time curve from time 0 to 2 hrs (0-2).
High VAS assesses the effect experienced by the participant on a 100 mm unipolar VAS, where responses are unidirectional and range from a response of 'none' (score of 0 mm) to 'extremely' (score of 100 mm). Emax = Maximum observed score.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| MS Contin (morphine sulfate, controlled release) | ACTIVE_COMPARATOR | - |
| EMBEDA (morphine sulfate / naltrexone hydrochloride) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage |
| MS Contin (morphine sulfate, controlled release) | DRUG | Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage |
| EMBEDA (morphine sulfate / naltrexone hydrochloride) | DRUG | Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage |
Inclusion Criteria: * Subject is a recreational opioid user who is NOT physically dependent on opioids based on Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) criteria, and the Naloxone Challenge. A recreational opioid user is defined as recreationall...
MS Contin is an investigational small molecule being studied for the treatment of nondependent opioid abuse, episodic. It is a controlled-release morphine formulation. The drug is in Phase 1 clinical development and is not approved for this use.
MS Contin is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. The company is conducting clinical research on this drug for the treatment of nondependent opioid abuse, episodic.
MS Contin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed for this drug.
MS Contin has one completed clinical trial, NCT01380093, which was a Phase 1 study. The trial evaluated the abuse potential of orally administered crushed MS Contin compared to crushed Embeda and placebo in non-dependent recreational opioid users.
No, MS Contin is not the same as Embeda. MS Contin is a controlled-release morphine formulation, while Embeda is a different drug. In a clinical trial, MS Contin was compared against Embeda and placebo to assess abuse potential.